Tumbleweed, a Vienna and Delft start-up that rents out laboratory space in orbit, has raised €6.9 million, Austria's largest space-tech seed round to date. The pitch to drug makers and universities is a price: an experiment in microgravity for about €15,000, against the years of paperwork and specialist engineering that space research usually demands. The money pays for three missions in 2027 and a re-entry vehicle to bring samples home from 2028.

Image: Tumbleweed. Credit: Tumbleweed, via Tech.eu.

US-based PactVC led the round, with Munich's Vanagon Ventures, early backer Prototype Capital, founder fellowship EWOR and international angels taking part, according to the company and reporting by Tech.eu and Payload. The valuation was not disclosed.

The raise comes four months after Tumbleweed's first satellite, Oasis Alpha, which the company describes as Austria's first commercial satellite, launched on SpaceX's Transporter-17 rideshare on 7 July 2026. It carried experiments for four customers, all first-time users of space, and was fully booked and paid for upfront a year before launch, the company says.

Space as a cloud service

Tumbleweed's product is a pre-certified "Pod", a laboratory in a box that customers fill with their equipment, test in their own facilities and hand over for launch. In orbit, each Pod works like a remote server that researchers monitor and control from the ground. Chief executive Julian Rothenbuchner told Tech.eu that the bottleneck is "the entire process of accessing microgravity", not the rocket. Payload preparation, safety approval and operations can add years to a research project.

The company says Oasis Alpha showed newcomers could run experiments in three to four months for around €30,000; the current entry offer is €15,000, including the Pod, launch and operations. It reports a customer conversion rate of about 40% and says the 2027 missions are expected to carry more than ten customers, from medical research, biotech and agritech labs. These figures come from the company and have not been independently verified.

The sceptic's case

The commercial case for research and manufacturing in orbit is still unproven. Cody Tranbarger of Atlas Venture has written that the fully loaded cost of space-based biomanufacturing "is largely unknowable today", with current processes producing "milligrams to grams of material at best", as Trending Topics noted. Tumbleweed is also not alone: US companies and Wales-based Space Forge are chasing similar markets, and launch capacity is tight. Rothenbuchner says the company is talking to launch providers in the US, Europe and Asia-Pacific. "We're not dependent on American launch providers, and we can't afford to be," he said.

Why it matters for Europe

For Austria, a country with little space industry, the round is a signal. "Companies like these strengthen domestic value creation, create skilled jobs, and demonstrate that Austria is internationally competitive in demanding future technologies," said federal innovation minister Peter Hanke. For Europe's pharma and biotech sector, the bigger question is whether cheap orbital access becomes routine R&D infrastructure or stays a niche.

Next comes Oasis Beta in 2028, the first mission meant to return physical samples to Earth. Tumbleweed is building its own re-entry vehicle, the riskiest and most capital-intensive part of the plan, and one a €6.9 million seed round alone is unlikely to finish.

Sources

• Tech.eu, "Tumbleweed raises record €6.9M seed round to bring microgravity research to the masses", 3 November 2026
• Payload, "Tumbleweed Raises €6.9M to Build its Own Reentry Vehicle", November 2026
• Trending Topics, "Tumbleweed Raises €6.9 Million Seed Round", November 2026